By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

PellePharm, Inc 

275 Middlefield Road
Suite 100
Menlo Park  California  94025  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

PellePharm is developing patidegib, a novel hedgehog pathway inhibitor, to treat basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in two phase 2 clinical trials for the treatment of BCCs and Gorlin Syndrome.

YEAR FOUNDED:

2012

LEADERSHIP:

Founders: Ervin Epstein, Philip Beachy and Jean Tang

CMO: Karl Beutner


Key Statistics


Email: info@pellepharm.com
Ownership: Private

Web Site: PellePharm, Inc
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
//-->